Refining Breast Cancer Classification by Multiplexed Imaging
Breast cancer progression can vary significantly between patients. Even within the same tumor, different areas may be composed of different types of cells and characterized by different tumor structures. This heterogeneity makes it challenging to ascertain the severity of a tumor and assess its molecular subtype, thereby affecting the precision of diagnosis and the choice of the most effective treatment approach.
Publication date: Available online 19 February 2020Source: Molecular and Cellular EndocrinologyAuthor(s): Tenghua Yu, Hong Cheng, Zhijuan Ding, Zhiliang Wang, Lixia Zhou, Peng Zhao, Shengxing Tan, Xue Xu, Xianming Huang, Manran Liu, Meixi Peng, Yu-an QiuAbstractRescue chemotherapy is usually the preferred treatment for patients with advanced estrogen receptor-positive (ER+) breast cancer with endocrinotherapy resistance. However, these patients often simultaneously show a poor response to cytotoxic drugs, and thus the detailed mechanism of this resistance needs to be further investigated. Our previous research indicated th...
Conclusion GRPR and integrin αvβ3 expression results are complementary to 18F-FDG PET/CT findings, and are also significantly correlated with hormone receptors associated with aggressive subtypes. These results may pave the way for GRPR and integrin αvβ3 targeted imaging with 68Ga-labeled molecules and systemic radionuclide treatment with 177Lu-labeled compounds.
Conclusion EORTC criteria and PERCIST had early predictive value to long-term outcome, but moderate value for pCR. Furthermore, PERCIST might show more potential than the EORTC criteria and conventional PET-based parameters to predict prognosis in breast cancer patients following two cycles of neoadjuvant chemotherapy. Video abstract: see http://links.lww.com/NMC/A162.
A patient with breast cancer at risk of infertility from adjuvant chemotherapy has given birth 5 years after having immature oocytes removed, matured in the laboratory, and then frozen.Medscape Medical News
This article reviews current data and ongoing research on atezolizumab for the treatment of breast cancer. Results of atezolizumab monotherapy trials in the context of other early immune checkpoint blockade trials in breast cancer are discussed as well as data from combination clinical trials with chemotherapy in both early stage and metastatic breast cancer. We focus on the safety and efficacy analyses from the phase III IMpassion trial that led to FDA and EMA approval of atezolizumab and nab-paclitaxel in patients whose tumor tested positive for PD-L1 by the Ventana SP142 companion diagnostic immunohistochemical assay.Ex...
WEDNESDAY, Feb. 19, 2020 (American Heart Association News) -- Red dresses and pink ribbons have helped millions of Americans become aware of the separate tolls heart disease and breast cancer take on women. But not everyone is aware of how the...
The publisher regrets that the author information was incorrect in the footnote. This has been corrected for the online version. The correct information is “Worapol Ngamcherdtrakul, PhD, is a scientist at PDX Pharmaceuticals. Dr. Ngamcherdtrakul's research is focused on developing nanoparticles for cancer-targeted co-delivery of drug and siRNA and developing topical formulations of a nanotechnology for skin diseases. He also leads the cancer immunoth erapy program at PDX Pharmaceuticals”.
Find out how genomic testing can help steer treatment decisions in metastatic breast cancer.JCO Precision Oncology